share_log

Alnylam Pharmaceuticals | 8-K: Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals | 8-K: Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

阿里拉姆制药 | 8-K：Alnylam Pharmicals公布2024年第二季度财务业绩并重点介绍近期活动
美股SEC公告 ·  2024/08/01 20:16

Moomoo AI 已提取核心信息

Alnylam Pharmaceuticals delivered robust Q2 2024 financial results with global net product revenues reaching $410 million, representing 34% YoY growth. The performance was primarily driven by its TTR franchise, which grew 37% YoY to $307 million, with AMVUTTRA contributing $230 million. GIVLAARI and OXLUMO generated combined revenues of $103 million, up 25% YoY.The company reported positive topline results from the HELIOS-B Phase 3 study of vutrisiran in ATTR cardiomyopathy patients, demonstrating 28% reduction in composite cardiovascular events and 36% reduction in all-cause mortality. Based on these results, Alnylam plans to submit a supplemental New Drug Application using a Priority Review Voucher.Given the strong performance, Alnylam raised its 2024 financial guidance, increasing combined net product revenue forecast to $1,575-1,650 million from $1,400-1,500 million previously. The company also updated its net revenues from collaborations guidance to $575-650 million, reflecting recent modifications to its Regeneron collaboration agreement.
Alnylam Pharmaceuticals delivered robust Q2 2024 financial results with global net product revenues reaching $410 million, representing 34% YoY growth. The performance was primarily driven by its TTR franchise, which grew 37% YoY to $307 million, with AMVUTTRA contributing $230 million. GIVLAARI and OXLUMO generated combined revenues of $103 million, up 25% YoY.The company reported positive topline results from the HELIOS-B Phase 3 study of vutrisiran in ATTR cardiomyopathy patients, demonstrating 28% reduction in composite cardiovascular events and 36% reduction in all-cause mortality. Based on these results, Alnylam plans to submit a supplemental New Drug Application using a Priority Review Voucher.Given the strong performance, Alnylam raised its 2024 financial guidance, increasing combined net product revenue forecast to $1,575-1,650 million from $1,400-1,500 million previously. The company also updated its net revenues from collaborations guidance to $575-650 million, reflecting recent modifications to its Regeneron collaboration agreement.
阿里拉姆制药发布了2024年第二季度强劲的财务业绩，全球净产品营业收入达到41000万，同比增长34%。业绩主要受其TTR业务的推动，同比增长37%，达到30700万，其中AMVUTTRA贡献了23000万。GIVLAARI和OXLUMO的合计营业收入为10300万，同比增长25%。该公司报告了来自HELIOS-b 3期研究的积极顶线结果，结果显示在ATTR心肌病患者中，复合心血管事件减少28%，全因死亡率减少36%。基于这些结果，阿里拉姆计划提交使用优先审查凭证的补充新药申请。鉴于强劲的业绩，阿里拉姆提高了其2024年的财务指引，将合计净产品营业收入预测从之前的140000-150000万上调至157500-165000万。该公司还更新了其来自合作的净营业收入指引，调整为57500-65000万，反映了与Regeneron合作协议的近期修改。
阿里拉姆制药发布了2024年第二季度强劲的财务业绩，全球净产品营业收入达到41000万，同比增长34%。业绩主要受其TTR业务的推动，同比增长37%，达到30700万，其中AMVUTTRA贡献了23000万。GIVLAARI和OXLUMO的合计营业收入为10300万，同比增长25%。该公司报告了来自HELIOS-b 3期研究的积极顶线结果，结果显示在ATTR心肌病患者中，复合心血管事件减少28%，全因死亡率减少36%。基于这些结果，阿里拉姆计划提交使用优先审查凭证的补充新药申请。鉴于强劲的业绩，阿里拉姆提高了其2024年的财务指引，将合计净产品营业收入预测从之前的140000-150000万上调至157500-165000万。该公司还更新了其来自合作的净营业收入指引，调整为57500-65000万，反映了与Regeneron合作协议的近期修改。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Channel Therapeutics
    CHRO
    -- 1.900
    泰坦制药
    TTNP
    -- 3.8350
    LakeShore Biopharma
    LSB
    -- 2.723
    Rigel Pharmaceuticals
    RIGL
    -- 20.130
    Veru Inc
    VERU
    -- 0.975
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球股市新风口在哪里？
    ▪️加密货币政策能否利好crypto？ ▪️关税政策能否利好中概等海外资产？ ▪️在特朗普政策下，有哪些投资机会值得关注？ 展开
    离川普上台只有7天了～